Scott Shapiro, MD
Clinical Cardiac Electrophysiology · Chevy Chase, MDNPI 1902967961
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,392 of the $4,167 with a category attached, or 81.4%. 32 manufacturers reported payments, led by Abbott at 36.0% of the total. 2025 is the largest year on record at $1,690, 5.8 times the $290 reported in 2019. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in MD, where the typical reported total is $15,262.
Across 137 payments — averaging $30.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Amgen$466
- E.r. Squibb & Sons, L.L.C.$357
- Kerecis Limited$221
- Philips North America LLC$220
- Johnson & Johnson$162
- plus $1K from 26 others
What the payments were for
- Travel & lodging$71317%
- Food & beverage$3,39281%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 21 | $1,500 |
| Amgen | 20 | $466 |
| E.r. Squibb & Sons, L.L.C. | 11 | $357 |
| Kerecis Limited | 1 | $221 |
| Philips North America LLC | 16 | $220 |
| Johnson & Johnson | 9 | $162 |
| Baxter Healthcare | 8 | $159 |
| Medicomp Inc | 3 | $132 |
| Novartis | 7 | $118 |
| Esperion Therapeutics, Inc. | 5 | $117 |
| Sanofi-aventis U.S. LLC | 4 | $78 |
| AstraZeneca | 4 | $66 |
| Alnylam Pharmaceuticals Inc. | 2 | $65 |
| AbbVie | 3 | $56 |
| Novo Nordisk | 2 | $51 |
| Boston Scientific | 2 | $50 |
| Actelion Pharmaceuticals US, Inc. | 1 | $40 |
| Medtronic(2 entities) | 3 | $37 |
| Biosense Webster, Inc. | 1 | $29 |
| Bardy Diagnostics, Inc. | 2 | $28 |
| Bristol Myers Squibb | 1 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $24 |
| Merck | 1 | $21 |
| Terumo Medical Corporation | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Itamar Medical Inc | 1 | $14 |
| Bridgebio Pharma, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 SurgiClose$664
- AVEIR$626
- Kerecis Omega3 GraftGuide$221
- Kerecis Omega3 Marigen$221
- Confirm Rx$130
- CAMZYOS$125
How this compares
$4,167 in reported general payments places this provider in the 20th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
See all clinical cardiac electrophysiology providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 425 | $594,868 |
| XareltoRivaroxaban | 179 | $241,427 |
| JardianceEmpagliflozin | 61 | $83,026 |
| EntrestoSacubitril/Valsartan | 47 | $73,003 |
| MultaqDronedarone Hcl | 43 | $68,620 |
| Repatha SureclickEvolocumab | 41 | $55,056 |
| FarxigaDapagliflozin Propanediol | 49 | $47,321 |
| JanuviaSitagliptin Phosphate | 25 | $31,848 |
| Repatha SyringeEvolocumab | 18 | $25,551 |
| OzempicSemaglutide | 18 | $19,395 |
| Ezetimibe | 403 | $16,418 |
| Rosuvastatin Calcium | 673 | $15,886 |
| MyrbetriqMirabegron | 13 | $14,505 |
| MounjaroTirzepatide | 11 | $12,500 |
| Metoprolol Succinate | 486 | $10,815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $162 | $241,427179 claims |
| Boehringer IngelheimJardiance | $13 | $83,02661 claims |
| NovartisEntresto | $118 | $73,00347 claims |
| Sanofi-aventis U.S. LLCMultaq | $78 | $68,62043 claims |
| AstraZenecaFarxiga | $66 | $47,32149 claims |
| MerckJanuvia | $21 | $31,84825 claims |
| Novo NordiskOzempic | $51 | $19,39518 claims |
| AbbVieSynthroid | $56 | $5,89550 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
Other clinical cardiac electrophysiology in Chevy Chase
- Sean BeinartRockville$315K
- Charles LoveBaltimore$238K
- Hugh CalkinsBaltimore$202K
- Paresh ShahBaltimore$97K
- Helen BaroldRockville$83K
- Jonathan ChrispinBaltimore$77K
- Sung LeeTakoma Park$68K
- Stephen ShorofskyBaltimore$63K
- Nilofar IslamTowson$61K
- Arooge TowheedLargo$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.